NVO vs VKTX: How Novo Nordisk and Viking Therapeutics Compare (2026)
Short answer
NVO (Novo Nordisk) and VKTX (Viking Therapeutics) are often compared because they share investment themes, but they are different businesses. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Neither is universally better: pick by which thesis you are expressing and what you already own. This is descriptive, not a recommendation.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
What does Viking Therapeutics (VKTX) do?
Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its highest-profile program is VK2735, a dual GLP-1 and GIP receptor agonist for obesity, being developed in both injectable and oral forms, which puts Viking among the most closely watched challengers in the booming weight-loss drug market dominated by Novo Nordisk and Eli Lilly. Viking is also developing VK2809, a thyroid-hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH/MASH), and VK0214 for a rare disease (X-linked adrenoleukodystrophy). As a clinical-stage company, Viking has no approved products and generates essentially no product revenue, funding itself from cash on its balance sheet. Headquartered in San Diego, California, VKTX is a speculative, binary biotech whose value hinges on clinical-trial outcomes and the eventual commercial path for its lead obesity drug.
NVO vs VKTX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Novo Nordisk is best understood through its own drivers, and Viking Therapeutics through its. The useful comparison is which set of drivers and risks you want exposure to.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
- VKTX drivers: Lead obesity program (VK2735); Pipeline breadth in metabolic disease.
NVO or VKTX: which should you pick?
The bottom line: NVO vs VKTX
NVO and VKTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVO and VKTX exposure against your real portfolio. It is not an investment adviser.
Build a basket around NVO with Walnut
Use Novo Nordisk as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between NVO and VKTX?
+
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is NVO or VKTX the better stock?
+
Walnut is informational, not investment advice. Neither is universally better; NVO and VKTX suit different views and risk levels. Compare what each does, how they make money, and the risks, then decide which fits your thesis and what you already own.
Should you own both NVO and VKTX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both before you add the second.
What are the risks of NVO vs VKTX?
+
NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. VKTX: Viking is a clinical-stage biotech with no approved products and essentially no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking funds itself from cash and may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVO or VKTX; figures are approximate and dated. Verify current data before investing.